Literatur
- 1
Abdelmalek M F, Angulo P, Jorgensen R A, Sylvestre P B, Lindor K D.
Betaine, a promising new agent for patients with nonalcoholic steatohepatitis:
results of a pilot study.
Am J Gastroenterol.
2001;
96
2711-2717
- 2
Adams L A, Angulo P.
Vitamins E and C fort he treatment of NASH: Duplication of results but lack
of demonstration of efficacy.
Am J Gastroenterol.
2003;
98
2348-2350
- 3
Angulo P, Lindor K D.
Treatment of non-alcoholic steatohepatitis.
Best Practice & Research Clinical Gastroenterology.
2002;
16
797-810
- 4
Caldwell S H, Hespenheide E E, Redick J A. et al .
A pilot study of thiazolidinedione, troglitazone in nonalcoholic steatohepatitis.
Am J Gastroenterol.
2001;
96
519-525
- 5
Chitturi S, Abeygunasekera S, Farrell G C. et al .
NASH and insulin resistance: Insulin hypersecretion and specific association
with the insulin resistance syndrome.
Hepatology.
2002;
35
373-379
- 6
Clark J M, Brancati F L.
Negative trials in nonalcoholic steatohepatitis: why they happen and what they
teach us.
Hepatology.
2004;
39
602-603
- 7
Emery M G, Fisher J M, Chien J Y. et al .
CYP2E1 activity before and after weight loss in morbidly obese subjects with
nonalcoholic fatty liver disease.
Hepatology.
2003;
38
428-435
- 8
Farrell G C.
Drugs and steatohepatitis.
Sem Liver Dis.
2002;
22
185-194
- 9
Fujikawa K, Ohata K, Honda T. et al .
Nonalcoholic steatohepatitis with improved hepatic fibrosis after weight reduction.
Intern Med.
2004;
43
289-294
- 10
Gulbahar O, Karasu Z A, Ersoz G. et al .
Treatment of non-alcoholic steatohepatitis with N-acetylcysteine.
Gastroenterology.
2000;
118
A1444
- 11
Harrison S A, Ramrakhiani S, Brunt E M, Anbari M A, Cortese C, Bacon B R.
Orlistat in the treatment of NASH: a case series.
Am J Gastroenterol.
2003;
98
926-930
- 12
Harrison S A, Torgerson S, Hayashi P, Ward J, Schenker S.
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic
steatohepatitis.
Am J Gastroenterol.
2003;
98
2485-2490
- 13
Kiyici M, Gulten M, Gurel S. et al .
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
Can J Gastroenterol.
2003;
17
713-718
- 14
Kugelmas M, Hill D B, Vivian B, Marsano L, McClain C J.
Cytokines and NASH: a pilot study of the effects of lifestyle modification and
vitamin E.
Hepatology.
2003;
38
413-419
- 15
Laurin J, Lindor K D, Crippin J S. et al .
Ursodeoxycholic acid or clofibrate in the treatment of NASH: a pilot study.
Hepatology.
1996;
23
1464-1467
- 16
Lazarides K N, Gores G J, Lindor K D.
Urosdeoxycholic acid mechanisms of action and clinical use in hepatobiliary
disorders.
J Hepatol.
2001;
35
134-146
- 17
Lavine J E.
Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.
J Pediatr.
2000;
136
734-738
- 18
Li Z, Yang S, Lin H, Huang J, Watkins P A, Moser A B, Desimone C, Song X Y, Diehl A M.
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic
fatty liver disease.
Hepatology.
2003;
37
343-350
- 19
Lieber C S, Leo M A, Mak K M, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli L M.
Acarbose attenuates experimental non-alcoholic steatohepatitis.
Biochem Biophys Res Commun.
2004;
315
699-703
- 20
Lindor K D, Kowdley K V, Heathcote E J. et al .
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results
of a randomized trial.
Hepatology.
2004;
39
770-778
- 21
Merat S, Malekzadeh R, Sohrabi M R. et al .
Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized
controlled study.
J Hepatol.
2003;
38
414-418
- 22
Miglio F, Rovati L C, Santoro A, Setnikar I.
Efficacy and safety of oral betaine gluconate in non-alcoholic steatohepatitis.
A double-blind, randomised, parallel-group, placebo-controlled prospective clinical
study.
Arzneimittelforschung.
2000;
50
722-727
- 23
Neuschwander-Tetri B A, Brunt E M, Wehmeier K R, Sponseller C A, Hampton K, Bacon B R.
Interim results of a pilot study demonstrating the early effects of the PPAR-gamma
ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis
and body weight in patients with non-alcoholic steatohepatitis.
J Hepatol.
2003;
38
434-440
- 24
Neuschwander-Tetri B A, Caldwell S H.
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.
Hepatology.
2003;
37
1202-1219
- 25
Neuschwander-Tetri B A, Brunt E M, Wehmeier K R, Oliver D, Bacon B R.
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma
ligand rosiglitazone.
Hepatology.
2003;
38
1008-1017
- 26
Promrat K, Lutchman G, Uwaifo G I, Freedman R J, Soza A, Heller T. et al .
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Hepatology.
2004;
39
188-196
Prof. Dr. Hans-Peter Buscher
Medizinische Klinik II, DRK-Kliniken Berlin-Köpenick
12559 Berlin
Phone: 030/3035 3319
Fax: 030/3035 3321
Email: h.buscher@drk-kliniken-koepenick.de
